A multiplex RPA-CRISPR/Cas12a-based POCT technique and its application in human papillomavirus (HPV) typing assay

Yan Liu,Zhujun Chao,Wei Ding,Tanfeng Fang,Xinxian Gu,Man Xue,Wei Wang,Rong Han,Wanping Sun

DOI: https://doi.org/10.1186/s11658-024-00548-y

2024-03-10

Cellular & Molecular Biology Letters

Abstract:Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary and initiating factor for cervical cancer. With over 200 identified HPV types, including 14 high-risk types that integrate into the host cervical epithelial cell DNA, early determination of HPV infection type is crucial for effective risk stratification and management. Presently, on-site immediate testing during the HPV screening stage, known as Point of Care Testing (POCT), remains immature, severely limiting the scope and scenarios of HPV screening. This study, guided by the genomic sequence patterns of HPV, established a multiplex recombinase polymerase amplification (RPA) technology based on the concept of "universal primers." This approach achieved the multiple amplification of RPA, coupled with the CRISPR/Cas12a system serving as a medium for signal amplification and conversion. The study successfully constructed a POCT combined detection system, denoted as H-MRC12a (HPV—Multiple RPA—CRISPR/Cas12a), and applied it to high-risk HPV typing detection. The system accomplished the typing detection of six high-risk HPV types (16, 18, 31, 33, 35, and 45) can be completed within 40 min, and the entire process, from sample loading to result interpretation, can be accomplished within 45 min, with a detection depth reaching 1 copy/μL for each high-risk type. Validation of the H-MRC12a detection system's reproducibility and specificity was further conducted through QPCR on 34 clinical samples. Additionally, this study explored and optimized the multiplex RPA amplification system and CRISPR system at the molecular mechanism level. Furthermore, the primer design strategy developed in this study offers the potential to enhance the throughput of H-MRC12a detection while ensuring sensitivity, providing a novel research avenue for high-throughput detection in Point-of-Care molecular pathogen studies.

cell biology,biochemistry & molecular biology

What problem does this paper attempt to address?

The paper aims to address the following issues:

Early identification of current high-risk human papillomavirus (HR-HPV) infection types is crucial for effective risk stratification and management. Although HR-HPV infection is known to be closely related to the occurrence of cervical cancer, the point-of-care testing (POCT) technologies currently used during cervical cancer screening are still immature, which severely limits the scope and application scenarios of HPV screening. Therefore, this study proposes a novel POCT technology based on Multiplex Recombinase Polymerase Amplification (Multiplex RPA) and the CRISPR/Cas12a system to achieve rapid and accurate detection of six major high-risk HPV types (16, 18, 31, 33, 35, and 45). This system can complete detection within 40 minutes, and the entire process from sample loading to result interpretation can be completed within 45 minutes, with a detection sensitivity of 1 copy per microliter. Validation of 34 clinical samples through real-time quantitative PCR (QPCR) demonstrated the system's reproducibility and specificity.

In addition, the study also explored and optimized the molecular mechanisms of the Multiplex RPA amplification system and the CRISPR system, and developed a primer design strategy to improve the throughput of H-MRC12a detection while ensuring its sensitivity. This provides a new research direction for high-throughput detection in POCT molecular pathogen studies.